HYALRIPAYER-02 Chondropreparant, 2 ml syringe 1pc.

Chondroparative. The state of joint metabolism, viscoelastic and protective properties of synovial fluid are largely determined by the concentration of hyaluronic acid, a specific proteoglycan concentrated in cartilage, synovial membranes and other connective tissue structures of the body. The action of GUALRIPAYER-02 gel material (chondropreparant) is based on biological stimulation of natural metabolism processes, by which physiological and rheological status of synovial fluid improves. GUALRIPAYER-02 gel material (chondropreparant) promotes deceleration of articular cartilage destruction in conjunction with the processes of restoration of synovial fluid homeostasis.

Gel material HYALRIPAIER-02 (chondropreparant) restores effective concentration of hyaluronic acid in the matrix that leads to stimulation of fibroblasts and chondrocytes. Intermediate products of hyaluronic acid degradation have angiogenic, immunostimulatory and anti-inflammatory effects.

Gel material GIALRIPAYER-02 (chondropreparant) being a bioactive composition of modified hyaluronic acid with ascorbic acid and amino acids participating in the synthesis of collagen makes it possible to carry out directed delivery of active substances directly to the damaged connective tissue structures.

The structural modification of hyaluronic acid (polymer cross-linking) in the gel material HIALRIPAYER-02 (chondropreparant) provides prolonged reconstructive action on the cartilaginous, ligamentary and connective tissue structures of joints and extremities damaged due to injuries or degenerative-dystrophic processes.

In intra-articular injection the catabolic products of the gel material HIALRIPAYER-02 (chondropreparant), released amino acids, including the essential lysine, together with vitamin C create a physiologically favorable environment for strengthening the metabolic activity of cells and start the synthesis of the main components of the cartilage and connective tissue intercellular matrix.

Vitamin C in the material participates in the metabolic transformation of glycine, proline and lysine. Proline hydroxylation is necessary for stabilizing the triple helix of collagen and lysine hydroxylation is very important for the formation of covalent bonds between collagen molecules during the formation of collagen fibrils. This process is decisive for the stabilization of the intercellular substance of all types of connective tissue.

Indications

as part of the complex therapy for the following diseases and conditions:

– treatment of osteoarthritis of I-III stages of the knee, hip and other synovial joints of degenerative-dystrophic or traumatic origin;

– The need to improve the viscoelastic and protective properties of synovial joint fluid;

– degenerative-dystrophic conditions of ligamentous apparatus, connective tissue and cartilage structures;

– arthritis in remission stage.

For the prevention of degenerative-dystrophic diseases of the musculoskeletal system;

In rehabilitation period after trauma and surgery.

Active ingredient

How to take, the dosage

In the joint cavity. The volume of material insertion and the selection of the injection needle is determined by the physician individually, depending on the anatomical and physiological characteristics and condition of the joint.

If there is an effusion in the joint, preliminary evacuation of excess synovial fluid is recommended.

Depending on the size of the joint it is necessary to inject up to 2 ml of GUALRIPAYER-02 gel material (chondropreparant) into the joint cavity once every 14 days for 6-8 weeks. The course can be repeated in 6-12 months. Treatment of several joints can be performed at one time.

The treatment with HIALRIPAIRE-02 (chondroparantine) gel material has effect only on the joint where the material is injected, HIALRIPAIRE-02 (chondroparantine) has no systemic effect.

The syringe, needle and residue of unused material must be disposed of immediately after the procedure.

Please note! Proper injection is extremely important for an effective treatment outcome.

The injection of HIALRIPAYER-02 gel material (chondropreparation) must only be carried out by professionals who are authorized to do so according to local regulations.

Toskani Laboratories Ltd is not liable for any consequences of improper use of HIALRIPAIRE-02 gel material (chondropreparant).

Interaction

Injection in combination with other drugs and products has not been investigated.

Special Instructions

General precautions for intra-articular injections should be observed.

Intra-articular gel material HIALRIPAYER-02 (chondropreparant) should not be injected if there are infected wounds, abrasions in the joint area, marked inflammation, significant intra-articular effusion, venous and lymphatic stasis on the side of the affected joint. Disinfectants containing quaternary ammonium salts must not be used for skin treatment prior to intraarticular injection. The material should be warmed to room temperature before injection.

The gel material HIALRIPAYER-02 (chondropreparant) must be gently injected into the joint cavity. After the injection of HIALRIPAIRE-02 gel (chondropreparant) it is recommended that the patient should be gentle and avoid excessive load on the joint for several days. During the course of HIALRIPAIRE-02 (chondroparantine) gel injection it is not permitted to introduce anesthetics or other pharmacological preparations into the cavity of the affected joint.

Do not use the product with damaged packaging.

Contraindications

hypersensitivity to the components of the material;

having a history of autoimmune disease or undergoing autoimmune therapy;

taking anticoagulants;

Severe inflammation or infection of the joint;

Presence of signs of active skin disease or skin infection in the vicinity of the injection site;

Pregnancy;

Lactation period.

Side effects

The intra-articular injection of GIALRIPAYER-02 gel material (chondropreparant) is well tolerated.

In rare cases there may be local secondary effects such as pain, sensation of warmth, intra-articular exudation; very rare – allergic reactions.

The undesirable effects should be reported to the local representatives of TOSKANI Laboratory LLC.

Similarities